- Home
- CAG vs NBIX Comparison
CAG vs NBIX Comparison
Compare CAG & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- NBIX
- Stock Information
- Founded
- CAG 1919
- NBIX 1992
- Country
- CAG United States
- NBIX United States
- Employees
- CAG N/A
- NBIX N/A
- Industry
- CAG Packaged Foods
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAG Consumer Staples
- NBIX Health Care
- Exchange
- CAG Nasdaq
- NBIX Nasdaq
- Market Cap
- CAG 12.8B
- NBIX 13.7B
- IPO Year
- CAG N/A
- NBIX 1996
- Fundamental
- Price
- CAG $25.70
- NBIX $145.88
- Analyst Decision
- CAG Hold
- NBIX Buy
- Analyst Count
- CAG 9
- NBIX 22
- Target Price
- CAG $30.44
- NBIX $164.81
- AVG Volume (30 Days)
- CAG 5.5M
- NBIX 926.1K
- Earning Date
- CAG 12-19-2024
- NBIX 02-05-2025
- Dividend Yield
- CAG 5.46%
- NBIX N/A
- EPS Growth
- CAG N/A
- NBIX 97.40
- EPS
- CAG 1.03
- NBIX 3.73
- Revenue
- CAG $11,928,800,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- CAG N/A
- NBIX $27.18
- Revenue Next Year
- CAG $1.50
- NBIX $17.92
- P/E Ratio
- CAG $24.97
- NBIX $39.13
- Revenue Growth
- CAG N/A
- NBIX 25.72
- 52 Week Low
- CAG $25.35
- NBIX $110.95
- 52 Week High
- CAG $33.24
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- CAG 33.17
- NBIX 70.01
- Support Level
- CAG $25.35
- NBIX $138.66
- Resistance Level
- CAG $28.10
- NBIX $144.24
- Average True Range (ATR)
- CAG 0.52
- NBIX 3.32
- MACD
- CAG -0.12
- NBIX 0.23
- Stochastic Oscillator
- CAG 12.55
- NBIX 96.20
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of fiscal 2024 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the us retail channel, with just 9% of fiscal 2024 revenue coming from international markets and 10% from foodservice.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.